tbuckley/cabot-search huggingface dataset:
AB1402 A double-blind, sham controlled prospective trial on the efficacy of pulsating electromagnetic field therapy in osteoarthritis using a new therapy device magneter FX
Authors: Z. Vekerdy-Nagy, E. Simkovics, Z. Sipos, Έ. Szabό, I. Tόth, Z. Bodnár, Z. Szekanecz
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The biologic effects of low-level magnetic fields on the human body have been studied since the 16th century. Pulsating electromagnetic fields (PEMF) may have biological effects due to electrical rather than magnetic forces. There have been very few scattered studies on the effects of PEMF on pain and function in rheumatic diseases. <h3>Objectives</h3> The objective of this double-blind, pacebo-controlled, prospective trial was to assess the influence of PEMF therapy on pain and range of motion (ROM) in peripheral joints and spine affected by osteoarthritis. We also wished to determine the potential effects of PEMF on the cardiovascular system. We used a newly developed device providing a highly specialized vibration package of electromagnetic field. <h3>Methods</h3> Altogether 127 patients consecutively admitted to one of the two rehabilitation centers were recruited between September 1, 2009 and October 31, 2010. Patients with painful osteoarthritis of the large joints (study group A) or that of the spine (study group B) were divided into two study groups and were randomly assigned to either PMEF or sham treatment. <h3>Results</h3> Compared to the sham-therapy group patients benefited from the magnetic therapy mainly in pain reduction in the hip and in the shoulder. The rotational movements improved the most. Due to these favourable changes illness intusiveness has decreased in all patients but it was significant only in the magnetic therapy group. Treatment protocol was acceptable for all participants participated in the study as reflected in the patients' satisfaction. We have not experienced any side effects during the study period. Blood pressure and heart rate changes were similar in both groups and could be attributed primarily to the relaxing position <h3>Conclusions</h3> In this prospective, placebo controlled trial, WOMAC, pain and ICF scores changed upon both PEMF and Sham treatment. PEMF was significantly superior to Sham in improving IIRS scores, as well as some dimensions in hip, cervical and lumbar spine mobility. Thus, PEMF may be an effective non-pharmacological treatment of large joint and spine OA. <h3>Disclosure of Interest</h3> None Declared
AB0441 Evaluation of nailfoldvideocapillaroscopy in behçet’s disease
Authors: A. Balkarli, Ü. Özkan, S. Temel, N. Ozhan, V. Cobankara
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Behçet's disease is a systemic vasculitis with the involvement of all kinds of veins and arteries and is characterized by repeating mucocutaneus and ocular involvement. <h3>Objectives</h3> We aimed to determine microvascular abnormalities in Behçet patients with nailfoldvideocapillaroscopy. <h3>Methods</h3> We included 82 patients who were diagnosed with Behçet's disease according to international diagnosis criteria. Patients were reviewed about smoking, Raynaud's phenomena and ischemic ulcers. Patients who had comorbidities including hypertension, smoking and Raynaud's phenomena were not included in this study. As a control group we enrolled 30 healthy individuals matched for age and sex and who were not smoking. We used videocapillaroscope (x200) for capillaroscopic evaluation. Patients were put to hand rest (protection from trauma) 2 weeks before the capillaroscopic procedure and hands were held in room temperature at least 20 minutes on the day of the procedure. Immersion oil was used for better evaluation. 8 fingers excluding thumbs were evaluated independently by 2 doctors, and signs were recorded to patient follow-up form. We evaluated capillary quantity, microhemorrhage, ectasied capillaries (neat-not neat), megacapillaries, avascular space, bushy capillaries, meandering capillaries, neovascularization and bizarre capillaries with nailfoldvideocapillaroscopy. Ectasied capillaries were defined as capillary diameter &gt;0.02 nm, megacapillaries as &gt;0.05 nm, and microhemorrhage was defined as hemorrhage determined in at least two fingers without trauma. <h3>Results</h3> Mean age for patients was 36.9±11.8 (17-63), disease starting age was 29.8±9.7 (14-60), disease duration was 7±8.3 years. Capillary quantity within one millimeter space was 10.17±1.235 (9-13). We determined megacapillary in two (2.4%), microhemorrage in 4 (4.9%), tortuosity in 75 (91.5%) and bizarre capillary in 8 (9.8%) patients. No pathological signs were observed in the control group. No association was found between capillaryscopic pathologies and age, disease starting age, disease duration and clinical signs. Tortuosity was more frequents in patients who had pulmonary artery involvement (6.6% vs 33%); however, the difference was not significant. <h3>Conclusions</h3> We found less specific capillaroscopic pathologies in our study when compared with other studies. The reason for that can be our patient choice as we did not include patients with hypertension, smoking and Raynaud's phenomena. Pathologies we detected might originate from vasculitic nature of Bahçet's disease. Further studies are needed to clarify the diagnostic and prognostic value of capillaroscopy in BD. <h3>Disclosure of Interest</h3> None Declared
Conservative management of a late rectal perforation following cold biopsy polypectomy
Authors: C. Luigiano, F. Ferrara, S. Miraglia, C. Favara, C. Fabbri, G. La Ferrera, C. Virgilio
Journal: Endoscopy (2012)

Bowel perforation is a rare complication of endoscopic polypectomy [1]. It may result from excessive stretching of the bowel wall during the movements of the endoscope, barotrauma, or as a direct result of endoscopic therapy or tissue sampling [1].
Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders
Authors: Joshua D. Lee, Peter D. Friedmann, Timothy W. Kinlock, Edward V. Nunes, Tamara Y. Boney, Randall A. Hoskinson, Donna Wilson, Ryan McDonald, John Rotrosen, Marc N. Gourevitch, Michael Gordon, Marc Fishman, Donna T. Chen, Richard J. Bonnie, James W. Cornish, Sean M. Murphy, Charles P. O’Brien
Journal: New England Journal of Medicine (2016)

Extended-release naltrexone, a sustained-release monthly injectable formulation of the full mu-opioid receptor antagonist, is effective for the prevention of relapse to opioid dependence. Data supporting its effectiveness in U.S. criminal justice populations are limited.
Tc-99m Albumin Scintigraphy To Monitor the Effect of Treatment in Protein-Losing Gastroenteropathy
Authors: SHYH-JEN WANG, SHIH-CHUAN TSAI, JOUNG-LIANG LAN
Journal: Clinical Nuclear Medicine (2000)

Tc-99m albumin scintigraphy is a noninvasive method for detecting protein-losing gastroenteropathy.Seven patients with protein-losing gastroenteropathy were evaluated with Tc-99m albumin scintigraphy. In addition, Tc-99m albumin scintigraphy was used to monitor the effect of treatment in five of these seven patients. The scintigraphic results were compared with serum albumin levels.All seven patients had positive results in the pretreatment images. Changes in scintigraphic findings in the five treated patients correlated well with changes in serum albumin level.Tc-99m albumin scintigraphy is useful not only for diagnosing protein-losing gastroenteropathy but also for monitoring the effect of treatment.
Forearm Splints Seen on Bone Scan in a Weightlifter
Authors: SURJIT S. WADHWA, ROBERT MANSBERG, VIVIAN B. FERNANDES, SHAHEEN QASIM
Journal: Clinical Nuclear Medicine (1997)

Periostitis from overuse is widely seen in athletes. The most common sites are the posterior aspect of the tibiae related to the insertion of the tibialis posterior muscle(shin splints), proximal femur at the insertion of the large adductor muscles (thigh splints), and in the humerus(arm splints). The authors describe a case of"forearm splints" in a weightlifter with elbow and forearm pain.
THU0095 Is Nephrolithiasis an Unrecognized Extra-Articular Manifestation in Ankylosing Spondylitis? A Prospective Population-Based National Cohort Study with Matched General Population Comparator Subjects
Authors: A.K. Jakobsen, L.T. Jacobsson, O. Patchan, J. Askling, L.E. Kristensen
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Several factors known to increase the risk of NL are at play in AS patients, namely clinical and subclinical bowel inflammation, altered calcium metabolism due to inflammatory cytokines, bone-remodeling and spinal immobility. <h3>Objectives</h3> To estimate the rates of nephrolithiasis (NL) in Swedish patients with a diagnosis of ankylosing spondylitis (AS) compared to matched comparator subjects from the general Swedish population. <h3>Methods</h3> This is a prospective population-based national cohort study based on linkage of data from <i>The Swedish Patient Register, The Swedish Register of Total Population and Population Changes</i>, <i>The Swedish Cause of Death Register, The Swedish Register of Education</i> and <i>The Swedish Biologics Register</i> (2001-2009). The rate of NL in AS patients was compared to population comparator subjects matched on age, sex, and date of study entry. Cox regression models were used to calculate Hazard Ratios (HR) with adjustment for comorbidities and anti-TNF treatment. <h3>Results</h3> A total of 8,572 AS patients and 39,639 matched general population comparators were included in the study contributing 49,258 person-years (py) respectively 223,985 py. Mean age at study entry was 46 years (inter quartile range 36-56 years) and 65% were male. The univariate HR of NL in AS patients compared to general population comparators was 2.44 (95%CI 2.09 to 2.84). Predictors of NL within the AS group included anti-TNF treatment (HR 1.6; 95%CI 1.2 to 2.1), prior diagnosis of IBD (HR 2.3; 95%CI 1.7 to 3.3) and prior diagnosis of NL (HR 16.4;95%CI 11.5 to 23.4). After adjustment for these confounders AS patients still had a significantly increased risk of NL diagnosis (HR 2.08; 95%CI 1.77 to 2.44) and for AS patients with anti-TNF treatment this risk was even higher (HR 3.02;95%CI 2.32 to 3.93) when compared to general population subjects. As can be seen in the figure, male sex was associated with a significantly higher risk of NL in both AS patients and general population comparators. <h3>Conclusions</h3> The risk of NL in AS patients is more than two-fold increased and seems to correlate with disease severity of AS. NL is suggested as a novel extra-articular manifestation in AS patients. IBD, previous history of NL, and male sex were identified as other predictors of NL in the AS population. <h3>Acknowledgements</h3> We are indebted to all colleagues and staff at our university departments, especially Pernilla Nilsson and Jonas Eriksson. This study was supported by grants from Lund University, The Skane region, Österlund and Kock Foundations, and Reumatikerförbundet. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3826
SAT0336 The Long-Term Effects of Sysadoa Treatment on Knee Osteoarthritis Symptoms and Progression of Structural Changes: Participants from the Osteoarthritis Initiative Progression Cohort
Authors: J. Martel-Pelletier, C. Roubille, J.-P. Raynauld, F. Abram, M. C. Hochberg, M. Dorais, P. Delorme, J.-P. Pelletier
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To explore the effects of commonly used medications for treatment of knee osteoarthritis (OA) on structural progression. <h3>Methods</h3> Participants (n=600) were selected from the Osteoarthritis Initiative (OAI) progression cohort (http://www.oai.ucsf.edu/) (n=1,390) who met the following criteria: 24 consecutive months of follow-up with clinical and imaging data including radiographs and magnetic resonance imaging (MRI) of the index (highest WOMAC pain) knee. Data for joint space width (JSW) were obtained from the OAI database and cartilage volume was measured using fully-automated MRI. <h3>Results</h3> Participants reported taking (+) (n=300) or not taking (-) (n=300) OA treatment (analgesic/NSAID) over 24 months, with or without glucosamine and chondroitin sulfate (Glu/CS). The +analgesic/NSAID subjects had higher WOMAC scores (p&lt;0.0001) and smaller JSW (p=0.013) reflecting more severe disease at baseline. In the -analgesic/NSAID group, subjects taking Glu/CS had a smaller loss of JSW at 12 months (p=0.057) and cartilage volume at 24 months in the medial central tibial plateau (p=0.022 univariate and p=0.025 multivariate analysis). In the +analgesic/NSAID group, the subjects taking Glu/CS had significantly lower WOMAC scores (pain, p&lt;0.0001; stiffness, p=0.0373; disability, p=0.0004) and higher KOOS scores at baseline as well as a smaller cartilage volume loss in the tibial plateau at both 12 (p=0.029) and 24 months (p=0.033). In the -analgesic/NSAID groups, those who took Glu/CS and had JSW at baseline higher than the median showed less cartilage volume loss at 24 months in the medial compartment (p=0.025) and condyle (p=0.01). <h3>Conclusions</h3> In both the +analgesic/NSAID and -analgesic/NSAID groups, participants who took Glu/CS had reduced loss of JSW and cartilage volume over 24 months. These effects of Glu/CS on structural changes support results from previous studies. <h3>Disclosure of Interest</h3> None Declared
Effect of Intragastric Balloon on Gastric Emptying Time in Humans for Weight Control
Authors: Hsin-Jung Su, Chia-Hung Kao, Wan-Chen Chen, Tan-Tan Chang, Chun-Yi Lin
Journal: Clinical Nuclear Medicine (2013)

This study evaluated the effect of fluid-filled intragastric balloon treatment on the scintigraphic gastric emptying times in humans for weight control.Ten obese patients were prospectively recruited in our study. Three participants followed a solid food diet, and 7 participants followed a liquid meal diet to evaluate their scintigraphic gastric emptying times before and 3 months after fluid-filled intragastric balloon treatment.The participants included 3 males and 7 females. The mean age, body mass index, and body weight before intragastric balloon treatment were 36.8 ± 9.16 years, 35.91 ± 8.86 kg/m(2), and 93.9 ± 24.09 kg, respectively. The mean body weight, body mass index, and body weight loss 3 months after the treatment were 80.2 ± 21.32 kg, 31.50 ± 8.90 kg/m(2), and 13.7 ± 6.60 kg, respectively. The solid gastric emptying times before and 3 months after intragastric balloon treatment were 114 ± 18.52 minutes and 375.33 ± 207.04 minutes, respectively. The liquid gastric emptying times before and after intragastric balloon treatment were 38.71 ± 15.91 minutes and 318.71 ± 168.07 minutes, respectively. Statistically significant differences were observed in the solid and liquid gastric emptying times before and 3 months after intragastric balloon treatment using the Wilcoxon t test (P = 0.027, P = 0.001). Significantly positive correlations were observed between body weight loss and solid and liquid gastric emptying times after intragastric balloon placement using the Spearman correlation (β = 1.0, P < 0.001; β = 0.95, P = 0.001).The solid and liquid scintigraphic gastric emptying half time is significantly longer after intragastric balloon treatment in humans. A significantly positive correlation between body weight loss and scintigraphic gastric emptying time was observed after intragastric balloon treatment. We can predict the effect of intragastric balloons on weight control through scintigraphic gastric emptying times after the treatment. The effect of intragastric balloons on weight loss may be reinforced by combining intragastric balloon treatment with medication that can reduce gastric motility.
SURG-20A MULTICENTER SURVIVAL ANALYSIS OF UPFRONT LASER-ABLATION FOR TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Authors: Alireza Mohammadi, Veronica Chiang, Thomas Beaumont, Paul Elson, Gene Barnett, Eric Leuthardt
Journal: Neuro-Oncology (2015)

SURG-20. A MULTICENTER SURVIVAL ANALYSIS OF UPFRONT LASER-ABLATION FOR TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA Alireza Mohammadi1, Veronica Chiang2, Thomas Beaumont3, Paul Elson1, Gene Barnett1, and Eric Leuthardt3; Cleveland Clinic, Cleveland, OH, USA; Yale University, New Haven, CT, USA; Washington University, St. Louis, MO, USA INTRODUCTION: Laser-ablation is a new treatment modality for difficult-to-access brain tumors. Limited data is available regarding the outcome of laser-ablation for patients with newly diagnosed glioblastoma (nGBM). We evaluated the outcomes of nGBM patients utilizing laserablation via the NeuroBlate system (NBS). METHODS: 32 nGBM patients had upfront treatment with NBS in Cleveland Clinic, Washington University inSt. Louis, andYaleUniversity (6/2011-12/2014).8patientswithmultifocal nGBMs or no radiation/chemotherapy after surgery were excluded. Study endpoints: progression-free survival (PFS time to progression or death from any cause), time to progression (TTP; like PFS but with censored 4 patients who died with causes other than progression), overall survival (OS time to death from any cause), disease-specific PFS (DS-PFS), and disease-specific OS (DS-OS). Deaths from reasons other than progression were considered a competing risk for DSPFS and DSOS. Extent of ablation was defined by NBS software as blue (438C for 10 minutes) and yellow (438C for 2 minutes) thermal-damage-threshold (TDT)-lines. Using recursive partitioning algorithm three prognostic groups were identified in respect to coverage of tumor by TDT-lines as favorable (n 1⁄4 8 patients); intermediate (n 1⁄4 9 patients); and unfavorable (n 1⁄4 7 patients). RESULTS: 58% were male and median age was 54 years. The median tumor volume was 9.33 cm. 18 (75%) patients progressed and 15 (62%) patients have died during extended follow up. Median OS is estimated to be 14.4 months, median TTP 5.3 months, and median PFS 4.3 months. In multivariate analysis, NBS coverage groups were significant prognostic factor for PFS (p 1⁄4 0.008), TTP (p 1⁄4 0.0005), DS-PFS (p 1⁄4 0.0002), and DS-OS (0.0001). Only age. 70 years (p 1⁄4 0.04) and tumor volume .11 cm (p 1⁄4 0.03) were significant poor prognostic factors for OS. CONCLUSIONS: The NBS coverage groups are independent predictor of all outcomes other than OS that can be translated as surgical extent of resection in nGBM outcome. Neuro-Oncology 17:v214–v220, 2015. doi:10.1093/neuonc/nov235.20 Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2015.
Latest studies fail to show that tamoxifen prevents breast cancer
Authors: Z. Kmietowicz
Journal: BMJ (1998)

Attempts to map out the role of tamoxifen for the prevention of breast cancer were set back last week when two new European studies failed to show that prophylactic treatment is beneficial in high risk women.

These latest findings contradict those of a US trial which was halted in April on the strength of interim results showing that the incidence of breast cancer was 45% lower among women taking tamoxifen than among those taking placebo (18 April, p 1187). It will be 2005 before we know the true value of tamoxifen and other antioestrogens, predict UK experts. Only when results from ongoing European trials are combined in a meta-analysis will it become clear whether this preventive treatment can save lives and which women are most likely to benefit from early intervention.

Commenting on his group's study results, Dr Trevor Powles, head of the breast unit at the Royal Marsden Hospital, London, said that it was not a surprise …
CLINICAL AND PROGNOSTIC SIGNIFICANCE OF THE ELECTROCARDIOGRAPHIC PATTERNS OF ACUTE CIRCUMFLEX CORONARY ARTERY OCCLUSION IN 254 CONSECUTIVE PATIENTS
Authors: Miquel Vives-Borrás, Abdel-Hakim Moustafa, Jesus Alvarez-Garcia, Andreu Ferrero-Gregori, Joan García-Picart, Jordi Balcells-Iranzo, Antonio Serra, Alessandro Sionis, Juan Cinca
Journal: Journal of the American College of Cardiology (2016)
Evaluation of Chemotherapy Response in Primary Bone Tumors with F-18 FDG Positron Emission Tomography Compared with Histologically Assessed Tumor Necrosis
Authors: CHRISTIANE FRANZIUS, JOACHIM SCIUK, CHRISTIAN BRINKSCHMIDT, HERBERT JÜRGENS, OTMAR SCHOBER
Journal: Clinical Nuclear Medicine (2000)

Purpose The purpose of this study was to evaluate the potential of positron emission tomography using F-18-fluoro-2-deoxy-D-glucose (FDG PET) to assess the chemotherapy response of primary osseous tumors compared with the degree of necrosis determined histologically. Patients and Methods Seventeen patients with primary bone tumors (11 osteosarcomas, 6 Ewing’s sarcomas) were examined using FDG PET and planar bone scintigraphy before neoadjuvant chemotherapy and before surgery. Tumor response was classified histologically according to Salzer-Kuntschik (grades I–III: good response; grades IV–VI: poor response). In both imaging methods, quantification was performed using tumor to nontumor ratios (T:NT). Results Histologically, 15 patients were classified as having good responses (grade I, n = 1; grade II, n = 6; grade III, n = 8) and two as having poor responses (grades IV and V). FDG PET showed more than a 30% decrease in T:NT ratios in all patients who had good responses. However, three of these patients had increasing bone scintigraphy T:NT ratios, and another five had decreasing ratios of less than 30%. The patients with poor responses had increasing T:NT ratios and decreasing ratios of less than 30%, respectively, using both imaging methods. Conclusions FDG PET seems to be a promising tool for evaluating the response of primary osseous tumors to chemotherapy. In this preliminary study, FDG PET was superior to planar bone scintigraphy.
Association of MB Compatibility with Successful Intrafamilial Kidney Transplantation
Authors: Rene J. Duquesnoy, Kathleen B. Annen, Marilyn M. Marrari, H. Myron Kauffman
Journal: New England Journal of Medicine (1980)

The MB system is a newly defined system of B-cell alloantigens closely associated with HLA-DR. We assessed the role of MB compatibility in renal transplantation in a retrospective study of 21 patients who had received a kidney transplant from a related donor matched for a single HLA haplotype. One-year transplant survival was closely correlated with the presence of a compatibile MB antigen in the unshared haplotype of the donor: Eight of eight rejected kidneys were obtained from MB-incompatible donors, and 12 of 13 successful transplants were from MB-compatible donors. The association between MB compatibility and allograft acceptance was highly significant (P = 4.4 x 10(-5)), but no significant relation could be demonstrated between transplant survival and donor-recipient compatibility for antigens of the HLA-A, B or DR loci. These findings suggest that match matching for MB may be critical for the selection of donors in intrafamilial kidney transplantation.
Outcomes In Splenic Marginal Zone Lymphoma: Analysis Of 108 Patients Treated In British Columbia (BC)
Authors: Katharine He Xing, Amrit Kahlon, Joseph M. Connors, Brian Skinnider, Randy D. Gascoyne, Laurie H. Sehn, Kerry J. Savage, Graham W. Slack, Tamara Shenkier, Richard Klasa, Alina S. Gerrie, Diego Villa
Journal: Blood (2013)